333 related articles for article (PubMed ID: 38008609)
41. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
Boldys A; Buldak L
World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
43. Update on cardiovascular risk in nonalcoholic fatty liver disease.
Johnston MP; Patel J; Byrne CD
Curr Opin Cardiol; 2021 Jul; 36(4):478-486. PubMed ID: 34059612
[TBL] [Abstract][Full Text] [Related]
44. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
45. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
[TBL] [Abstract][Full Text] [Related]
46. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
47. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
[TBL] [Abstract][Full Text] [Related]
48. Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk.
Westcott F; Dearlove DJ; Hodson L
Atherosclerosis; 2024 Jul; 394():117237. PubMed ID: 37633797
[TBL] [Abstract][Full Text] [Related]
49. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
50. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
51. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
[TBL] [Abstract][Full Text] [Related]
52. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
[TBL] [Abstract][Full Text] [Related]
53. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
[TBL] [Abstract][Full Text] [Related]
54. From NAFLD to MASLD: When metabolic comorbidity matters.
Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
[TBL] [Abstract][Full Text] [Related]
55. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Singh A; Buckholz A; Kumar S; Newberry C
Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474786
[TBL] [Abstract][Full Text] [Related]
56. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
57. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
58. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
59. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
[TBL] [Abstract][Full Text] [Related]
60. New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk.
Branković M; Dukić M; Gmizić T; Popadić V; Nikolić N; Sekulić A; Brajković M; Đokić J; Mahmutović E; Lasica R; Vojnović M; Milovanović T
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38275476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
